TLR2 and myasthenia gravis: On the one hand, the reduction of neuroinflammation and neuronal impairment could be achieved by targeting the activation of MG as follows: (1) by targeting TLRs that trigger MG activation, such as TLR2, TLR4, and TLR9 (Li et al., 2012; Zhou P. et al., 2016; Maatouk et al., 2018); (2) by targeting key signaling pathways for MG activation, such as the NF-κB signaling pathway (Singh et al., 2020); and (3) by targeting pro-inflammatory factors such as TNF-α (Barcia et al., 2012).